Stock 2005 SSY GROUP LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Highlights SSY Group Limited

Equities

2005

KYG8406X1034

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:07 2024-05-09 EDT 		5-day change 1st Jan Change
4.8 HKD +0.63% Intraday chart for SSY Group Limited +2.13% -2.83%
04-23 SSY Group Get Production, Registration Approval for Pneumonia Drug from Chinese Regulator MT
04-23 SSY Group Limited Obtains Approval for Drug Production and Registration for Linezolid for Oral Suspension CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
SSY Group Limited Obtains Approval for Drug Production and Registration for Linezolid for Oral Suspension
CI
SSY Group Logs Nearly 15% Boost in Q1 Profit
MT
SSY Group Limited Announces Update on Product Development
CI
SSY Group Limited Provides Update on Product Development
CI
SSY Group's Profit Jumps 17% in 2023
MT
SSY Group Limited Announces Final Dividend for the Year Ended 31 December 2023, Payable on 04 June 2024
CI
SSY Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023
CI
SSY Group Limited Announces Update on Product Development
CI
SSY Group Limited Obtains Approval for Drug Production and Registration for Nicorandil for Injection from the National Medical Products Administration of China
CI
SSY Group Limited Announces its Norepinephrine Bitartrate Obtains the Approval for Registration from the National Medical Products Administration of China to Become a Bulk Drug for the Preparations on the Market
CI
SSY Group Limited Receives Approval for Gliclazide Tablet
CI
SSY Group Limited Provides Update on Product Development
CI
SSY Group Limited Obtains the Approval for Drug Production and Registration for Propofol Medium and Long Chain Fat Emulsion Injection from the National Medical Products Administration of China
CI
SSY Group Gets Bulk Drug Approval in China
MT
SSY Group Limited Announces Update on Product Development
CI
SSY Obtains Chinese Bulk Drug Registration Nod for Lidocaine Hydrochloride
MT
SSY Group Limited Provides Update on Product Development
CI
SSY Group Limited Provides an Update on Product Development
CI
Ssy Group Limited Provides Update on Product Development
CI
SSY's Anti-Rhinitis Drug Passes Chinese Regulator's Consistency Evaluation Tests
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 2005 Stock
  4. News SSY Group Limited
  5. Highlights
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW